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Abstract. The nematode Caenorhabditis elegans (C. elegans) is a powerful model organism to study lifespan and aging,
protein aggregation, and neurodegeneration, as well as to carry out drug screenings. The C. elegans strain aex-3/T337 expresses
human pathogenic V337M mutant tau under a pan-neuronal promoter and presents uncoordinated locomotion, accumulation
of phosphorylated insoluble tau, and shortened lifespan. Herein we have used this strain to assay two compounds that could
affect tau aggregation and/or phosphorylation, and looked for phenotypic changes in their lifespan and motility. The first
compound is Thioflavin T (ThT), a member of the tetracycline family with protein antiaggregant properties, yet to be tested
in a tauopathy model. The second is a novel small molecule, NP103, a highly selective inhibitor of glycogen synthase kinase-
3 (GSK-3), the main kinase contributing to pathogenic tau hyperphosphorylation. Importantly, we find that ThT extends
lifespan of aex-3/T337 worms as it does with control N2 animals, showing both strains similar locomotion features under this
treatment. By contrast, NP103 improves the paralysis phenotype of aex-3/T337 mutants but not their lifespan. Our results
show that both treatments present beneficial effects for this model of tauopathy and encourage pursuing further investigations
on their therapeutic potential for AD and other tauopathies.
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INTRODUCTION
Aging is associated with a gradual decline of
physiological and cognitive functions [1], and is
a major risk factor for various neurodegenerative
diseases, including Alzheimer’s, Huntington’s, and
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Parkinson’s diseases [2]. Although aging is a com-
plex phenomenon, failure to maintain proper protein
homeostasis plays a major role [3, 4]. Dysfunctional
protein homeostasis results in protein misfolding and
aggregation, being these two hallmarks characteris-
tic of aging and age-related diseases [5]. Flavonoid
Thioflavin T (ThT) belongs to the tetracycline fam-
ily and is an amyloid-binding dye widely used for
neuropathological analysis able to inhibit aggrega-
tion of pre-formed amyloid fibrils in vitro [6–8]. ThT
has also been shown to promote longevity in the
nematode Caenorhabditis elegans (C. elegans) and to
significantly suppress amyloid- (A) aggregation-
mediated paralysis [9].
Tau is the major neuronal microtubule-associated
protein and its activity is regulated by its phos-
phorylation state [10]. Aberrant phosphorylation
and aggregation of tau have been linked to
axonal transport problems, synaptic malfunction
and neurodegeneration [11] and are found in sev-
eral neurodegenerative diseases collectively called
tauopathies. Glycogen synthase kinase-3 (GSK-3) is
the main kinase contributing to tau hyperphosphory-
lation, being hyperactivated in Alzheimer’s disease
(AD) [12, 13]. Tau aggregates are amyloid in nature
[14] and form neurofibrillary tangles that together
with A plaques are the two major histopathologi-
cal hallmarks of AD [12, 13]. During the last years
there is a growing interest in studying tau pathology
in neurodegeneration as well as tau as a therapeu-
tic target [15, 16]. In particular, studies have focused
in tau aggregation, hyperphosphorylation, and other
post-translational modifications [10, 17, 18].
The nematode worm C. elegans has become
intensely studied due to its experimental advantages
to investigate neuronal cell degeneration and death.
Particularly, its short lifespan has made C. elegans to
emerge as a powerful model organism for the study
of aging [19–21]. Moreover, it is also an important
model to study protein aggregation in aging as well
as the molecular mechanisms of drug action and dis-
ease pathogenesis [22, 23]. C. elegans has been used
as a model of various age-associated neurodegenera-
tive diseases, including AD [24], Parkinson’s [25, 26]
and Huntington’s disease [27]. Studying human tau
mutants in C. elegans has the advantage of avoiding
interference with endogenous tau, since the only tau
homologue in the worm, PTL-1, is only expressed
in a small subset of neurons [28, 29]. The C. ele-
gans strain aex-3/T337 expresses full-length human
tau bearing the pathogenic mutation V337M by using
the aex-3 pan-neuronal promoter and shows sufficient
similarities to human disease to give confidence that
they are relevant to the toxic mechanism of human
tauopathies [30, 31]. This line presents progressively
worsening uncoordinated locomotion, accumulation
of phosphorylated insoluble human tau, and short-
ened lifespan.
The structure of amyloidogenic intermediates,
such as those formed by A and tau, is highly con-
served [32], suggesting that compounds blocking
their formation independently of the protein they con-
tain could be useful for several protein aggregation
disorders. In fact, ThT and other tetracyclines can dis-
aggregate A oligomeric forms and other misfolded
proteins [33–36]. However, to our knowledge there
are no previous studies on the effects of these com-
pounds on tau neurotoxicity, even though ThT binds
tau aggregates and is also widely used as dye to stain
tau amyloid fibrils [37–39]. The use of therapeutic
compounds for aging-associated neurodegenerative
diseases in C. elegans has been recently reviewed,
but studies of ThT effects on tauopathy models are
not documented [23].
Because ThT was successfully used to improve the
phenotype of a C. elegans model of A pathology
[9], herein we have assayed this drug in the C. ele-
gans model of tauopathy aex-3/T337, and analyzed
whether it could improve the phenotype associated
to tau toxicity. Importantly, we find that ThT extends
the lifespan of aex-3/T337 worms. In addition, since
GSK-3 is the major kinase driving tau pathologic
hyperphosphorylation, we have also tested a novel
and highly specific GSK-3 inhibitor, NP103. This
novel compound improves significantly aex-3/T337
worms’ paralysis phenotype but shows no effects
on the extension of their lifespan. Our results indi-
cate that although both treatments can modulate
tau-neurotoxic uncoordinated phenotype, ThT ren-
ders more beneficial effects associated to aging for
this model of tauopathy.
MATERIALS AND METHODS
C. elegans strains
N2 (Bristol) was used as wild-type C. elegans [40].
Line aex-3/T337 [myo-2:GFP, aex-3:tau-V337M]
carries chromosomally integrated transgenes encod-
ing GFP and the 1N4R isoform of human tau
carrying the V337M FTDP-17 mutation with expres-
sion driven by the pan-neuronal promoter aex-3. This
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strain is GFP-positive and shows a pronounced unco-
ordinated phenotype [30].
Maintenance and treatment of nematode strains
C. elegans strains were propagated at 20◦C on solid
sterile Nematode Growth Medium (NGM) seeded
with 100 l spots of E.Coli (OP50) for food on p60
plates. They were transferred to a fresh plate every
3-4 days. Synchronized animals were prepared by
bleaching adult worms. Briefly, worms were col-
lected with sterile water from a p60 plate. After
washing all the bacteria from the supernatant they
were lysed with hypochlorite solution for a few min-
utes. Then they were washed and centrifuged under
a sucrose gradient. Finally, eggs were allowed to
grow overnight in M9 medium and hatchlings were
seeded on fresh NGM plates. The worms from L4
larvae stage (3 days old) were fed with the vehicle,
Thioflavin T, or the GSK-3 inhibitor (NP103) at dif-
ferent concentrations as specified in figure legends
and every single day they were transferred to a new
fresh plate containing the compound.
Lifespan assay and paralysis analysis
Lifespan assays were performed as described in
[9]. Briefly, twenty synchronized L4 worms were
transferred to a fresh p35 plate containing 4 ml of
agar in the presence or absence of 100 L of the
corresponding compound at different concentrations.
Both plates and compounds were prepared under ster-
ile conditions and spreading the compound over the
surface of the plate. We considered that the com-
pound had an even distribution throughout the 4 ml
of agar. At this point, someone different from the
scorer coded the plates so that the scoring was blind
to experimental conditions. Plates were allowed to
dry at room temperature for 1 h and then 60 L of a
concentrated suspension of E.Coli OP50 were spotted
to form a circular layer in the center of the plate. All
lifespan experiments were performed at 20◦C. Every
day animals were transferred to fresh plates prepared
the day before and next day nematodes were scored
as alive, dead or lost. We followed the same criteria
established in [9] to determine if a worm was dead
or not. Survival curves were plotted using Prism®
5.0 (GraphPad Software Inc, La Jolla, CA). At the
moment of the passage, motility was visualized by
the trails left by the worms crawling on the surface of
the new plates by an observer blind to the plates codes.
In the case of aex-3/T337, paralysis was analyzed by
a scorer blind to experimental conditions assigning
different values to worms with normal wild type-like
movement (value 3), slow movement (value 2), or
paralyzed (value 1), following a method to measure
A paralysis [41]. Paralyzed animals were distin-
guished from dead by testing movement by prodding
the body with the worm picker. The percentage of
aex-3/T337 worms scored with different values of
movement along time of treatment with vehicle or
NP103 was determined each day when passing the
animals to a fresh plate.
Reagents, enzymes, and substrates
[-33P]-ATP (1000–3000 Ci/mmol) was obtained
from Amersham Biosciences (cat n◦ AH9968). The
following human recombinant enzymes were pur-
chased from Upstate: GSK-3 (cat n◦ 14–306),
GSK-3 (cat n◦ 14–492), MAPK1/ERK1 (cat n◦
14–439), CDK1 (cat n◦ 14–450), and PKA (cat n◦
14–440), CK2 (cat n◦ 14–197). Human Recombi-
nant Cdk5/p35 was purchased from Invitrogen (cat
n◦ PV3000). The following enzyme substrates were
purchased from Upstate: myelin basic protein (cat
n◦ 13–104), histone H1 (cat n◦ 14–155), and Kemp-
tide (cat n◦ 20–199). The phospho-glycogen synthase
kinase peptide-2 (GS2) was purchased from Tocris
(cat n◦ 1352). The proprietary compound NP103
was provided directly by the company Noscira S.A.
Unless otherwise stated, all other reagents were of the
highest purity available from Sigma (St Louis, MO).
Enzymatic assays
Enzymatic assays were performed essentially as
described in [42]. Briefly, the activity of GSK-3
(both wild-type and C199A versions) was measured
with the FRET-based Z’-LYTE™ technology from
Invitrogen using the so-called “Ser/Thr-9” peptide,
a fluorescein- and coumarin-double-labeled 11-mer
based on the sequence of the human glycogen syn-
thase I containing Ser-641, as peptide substrate. The
assay was carried out at 25◦C according to the man-
ufacturer’s instructions in a final volume of 10 L
in 384-well low-volume round bottom black plates
(Corning, Corning, NY) with 50 mM Hepes pH
7.5, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-
35 as assay buffer. Enzyme concentration ranged
from 2 to 5 nM as determined by active-site titra-
tion with the well-known inhibitor CT99021. Unless
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otherwise stated, ATP and peptide concentrations
were 12.5 M and 2 M, respectively, corresponding
to their respective previously determined Km val-
ues. Typically, the assays were run during 1 h in the
presence or absence of compounds in a final DMSO
concentration of 1% and samples were processed
according to the manufacturer’s instructions. When
concentration responses of the compounds were eval-
uated, their potencies were determined as the negative
logarithm of the IC50 (i.e., the pIC50); as the experi-
ments were carried out by performing serial dilutions,
the range of concentrations was evenly distributed in
a logarithmic rather than a linear scale. pIC50s were
calculated by fitting the resulting data to Equation 1,
using the nonlinear regression function of Prism® 5.0
(GraphPad Software Inc, La Jolla, CA).
ATP competition
Recombinant human GSK-3 activity was assayed
in vitro at 0.5 mU/ L in the absence or presence of
NP103 (5 and 25 M) and increasing concentrations
of ATP (from 3.125 to 100 M) with [33P]-ATP
(0.025 Ci/L). GS2 peptide (62.5 M) was used
as substrate. Reaction was carried out in a final vol-
ume of 20 L for 30 min at 30◦C. After that, 15 L
aliquots were spotted onto P81 phosphocellulose
papers, washed four times in 1% phosphoric acid and
counted in a Trilux Microbeta scintillation counter.
Statistical analysis
Data were analyzed and plotted by using the
Graph Pad Prism® software (GraphPad Software Inc,
La Jolla, CA) and the IC50 was calculated from
the average of the logarithmic values obtained. The
results are expressed as mean SEM. Statistical analy-
sis was performed using one-way ANOVA followed
by Bonferroni’s multiple comparison test (selected
pairs) where p < 0.05 was considered significant. A
Chi-square test was used to compare movement dif-
ferences of aex-3/T337 under the indicated treatment.
RESULTS
The anti-aggregant compound Thioflavin T
extends the lifespan of the C. elegans model of
tauopathy aex-3/T337
To investigate if ThT could have any beneficial
effects on tauopathy models, we selected the C. ele-
gans model of tauopathy aex-3/T337 [30], and tested
different doses of ThT. In agreement with previ-
ous observations [30], we could confirm that these
worms presented an uncoordinated phenotype and a
shorter lifespan compared with wild type N2 strain
(not shown). Before analyzing the effects of ThT
in aex-3/T337 animals, we initially carried out con-
trol lifespan experiments using wild-type N2 worms
treated with different concentrations of this drug. The
treatment was started in synchronized worms when
they reached the L4 stage, and was maintained at
20◦C until the experiment was finished. Every day
animals were transferred to fresh plates prepared the
day before. First, we performed ThT dose-response
curves (10 M to 500 M) to establish the optimal
concentration rendering the maximum lifespan exten-
sion (Fig. 1A). Note that the highest ThT dose tested
(500 M) was toxic (Fig. 1A). However, lifespan
of N2 worms treated with 10, 25, or 50 M ThT
was significantly increased when compared to those
Fig. 1. Thioflavin T (ThT) extends lifespan of a C. elegans model of tauopathy. Dose–response Kaplan–Meier survival curve of synchronized
populations of wild-type (N2) worms (A) or mutant aex-3/T337 worms (B), exposed to 0 M (control) to 500 M ThT at 20◦C. These data
correspond to one representative experiment out of three independent assays (n = 20 worms per experiment and dose).
A. Gamir-Morralla et al. / ThT and GSK-3 Inhibition in a Tauopathy Model 51
non-treated (Fig. 1A). Next, we performed ThT dose-
response experiments using the aex-3/T337 strain and
obtained similar results (Fig. 1B). While 500 M ThT
resulted equally toxic as to N2 control animals, there
was a clear improvement of lifespan in aex-3/T337
worms exposed to lower doses of ThT (Fig. 1B).
Visual observation after 16 days of treatment revealed
that aex-3/T337 worms exposed to ThT presented a
phenotype reminiscent of that of wild type animals,
with improved locomotion (not shown).
A novel selective GSK-3 inhibitor improves the
uncoordinated phenotype of aex-3/T337 strain
without extending their lifespan
As GSK-3 is widely accepted as the major kinase
responsible for tau hyperphosphorylation (reviewed
in [43]), we studied whether its inhibition could
contribute to lifespan extension and/or improvement
in locomotion in aex-3/T337 worms. For that pur-
pose, we used a novel GSK-3 inhibitor, NP103, a
synthetic small molecule derived from the marine
compound Oroidin developed by Noscira S.A. [44,
45]. NP103 inhibits in vitro recombinant human
GSK-3 and GSK-3 with similar IC50s, of 0.56 M
and 0.29 M, respectively (Fig. 2A, B). The com-
pound shows a good solubility up to over 500 M
(slightly lower at very basic pH), a logP of 1.61, mem-
brane permeability and is stable in biological fluids.
Preliminary data in mice show NP103 having a very
good (>70%) oral bioavailability and readily crossing
the blood-brain barrier (20–25%).
In addition, increasing ATP concentrations can
overcome GSK-3 inhibition by NP103, thus
Fig. 2. Characterization of NP103 compound as GSK-3 selective inhibitor. A, B) NP103 inhibits GSK-3 and GSK-3 in vitro. Data represent
the mean values + SD of the percentage of enzymatic activity. Each data point was assayed in duplicates. IC50 values were calculated from
the concentration-response curves. C) Effect of different ATP concentrations on GSK-3 activity. A double-reciprocal Lineweaver-Burk
plotting of the enzyme kinetics in the presence of two different concentrations of NP103 is shown. Each point represents the mean value
of two independent experiments. No competition with substrate was observed (not shown). D) NP103 kinase inhibition selectivity profile.
A comparison among external and in-house obtained results in selected kinases.
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Fig. 3. NP103 shows minor effects on lifespan extension of pathogenic tau aex-3/T337 transgenic strain but improves their paralysis pheno-
type. A) Dose–response Kaplan–Meier survival curve of synchronized mutant aex-3/T337 worms exposed to different doses (0–250 M) of
NP103. B) Curve representing the percentage of aex-3/T337 worms non-treated (black line) or NP103 100 M treated (purple line) showing
wild type-like movement along time. One representative experiment out of three independent assays are shown in (A) and (B); (n = 20 worms
per experiment and dose). C) Statistical analysis of aex-3/T337 worms motility after 5 days of treatment with vehicle (control, C) or 100 M
NP103 (NP). Motility was scored assigning different values to worms with normal wild type-like movement (value 3), slow movement (value
2) or paralyzed (value 1). Data show means ± s.e.m of three independent experiments (n = 20 worms per experiment). Chi-square test was
performed (∗p < 0.05).
indicating that this compound acts as an ATP-
competitive inhibitor (Fig. 2C). Further in silico
docking studies confirmed the binding to the catalytic
active site of GSK-3. To assess compound’s selec-
tivity profile, its inhibitory properties were evaluated
against a panel of 231 different protein kinases by
an external CRO. Only a few protein kinases showed
significant inhibition and thus were selected for per-
forming detailed curve-response studies and IC50
calculation. As shown in (Fig. 2D), NP103 is a highly
selective inhibitor for both GSK-3 isoforms. We also
know that NP103 decreases tau protein phosphory-
lation in cell-based assays at the epitope Ser396 (a
site specifically phosphorylated by GSK-3 in cells)
without exerting cytotoxic effects (not shown) [44].
More recently, NP103 has been shown to inhibit tau
phosphorylation in vivo after intracerebral adminis-
tration in a mouse model of epilepsy [46]. Together,
these results make NP103 an especially interesting
molecule, since blocking the hyperphosphorylation
step of tau may be a prime target at which to halt the
pathogenic cascade.
C. elegans GSK-3 and human GSK-3 and GSK3
show a high degree of homology and conservation of
sequences crucial for kinase activity: the ATP bind-
ing site, the proton acceptor site and the activation
loop at the catalytic domain. Given that NP103 is
an ATP-competitive inhibitor, it is highly predictable
this compound would be able to equally inhibit
ATP-binding in the orthologues. Thus, we performed
lifespan assays in the pathogenic tau aex-3/T337
transgenic strain using NP103 at different doses.
Figure 3A shows that NP103 did not present tox-
icity at any concentration tested and produced no
major changes on lifespan extension of aex-3/T337
worms. In addition, none of the doses used showed
effects on wild type N2 worms or was able to pre-
vent the appearance of the paralysis phenotype that
occurs in aex-3/T337 animals since approximately
day 9. However, 100 M NP103 raised the percent-
age of animals showing normal locomotion along
time of treatment, being this increase statistically sig-
nificant at day 5 (Fig. 3B-D). This result indicates
that GSK-3 inhibition can improve the quality of
life of aex-3/T337 animals without extending their
lifespan.
DISCUSSION
Herein we have explored new benefits of ThT and
GSK-3 inhibition in the C. elegans model of tauopa-
thy aex-3/T337 that expresses the pathogenic mutant
form of human tau V337M [30, 31]. We demonstrate
that ThT extends lifespan in these transgenic worms,
improving their locomotion. By contrast, inhibition
of GSK-3 improves the paralysis phenotype of aex-
3/T337 worms with minor effects on their lifespan.
In C. elegans, tetracycline and its analogues,
including ThT, can reduce A oligomer and amyloid
fibrillar deposition because they can interact directly
in vivo with different A assemblies and reverse
their structures to non-amyloidogenic forms. In this
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way, these compounds protect transgenic C. elegans
strains from the paralysis phenotype of human A
associated toxicity. For instance, ThT can amelio-
rate detrimental effects during development of the
A aggregate-related pathology in C. elegans [9].
Notably, thioflavins bind aggregates containing dif-
ferent hyperphosphorylated forms of tau [37–39, 47].
However, ThT effects on tau aggregates are largely
unknown, although ThT can retard significantly tau
and phospho-tau aggregation in vitro [37]. The low-
est concentration of ThT used for anti-tau aggregation
in these in vitro assays was 30 M. Here we detect
effects of ThT on N2 worms and aex-3/T337 mutants
lifespan at 10, 25, and 50 M doses. Together these
observations could indicate that low concentrations
of ThT may be likely affecting different processes in
the worms but not tau aggregation. We cannot how-
ever exclude that higher ThT concentrations could
present combined effects both modifying tau aggre-
gation properties and other tau-independent cellular
functions.
In this regard, according to Alavez and collabora-
tors [9], amyloid-binding compounds such as ThT,
could act as a stress response mimetic and extend
lifespan and influence protein aggregation through
improved global protein homeostasis by affecting
chaperones and protein misfolding cascades. They
demonstrate that the pro-longevity effect of ThT
depends on the transcription factors heat shock factor-
1 (HSF-1) and the stress resistance and longevity
Nrf2-like factor SKN-1 [9]. HSF-1 is induced by
the accumulation of damaged proteins that controls
expression of the ubiquitination/proteasome pathway
for protein degradation preventing their aggregation
[48, 49].
In the tauopathy model used in our study, ThT
could be activating the ubiquitination/proteasome
pathway by inducing HSF-1. This step could pro-
mote the elimination of tau accumulation, as one
way of tau degradation can be proteasome-dependent
[50, 51]. A parallel induction of HSF-1 and SNK-1
transcription programs, including small heat-shock
protein and stress response encoding genes that in
turn promote longevity [9, 52, 53], could be also
acting this way in ThT-treated aex-3/T337 worms.
In this context, a very recent publication demon-
strates that molecular chaperones confer protection
against tau aggregation [54]. An additional recent
work shows that hydralazine, an activator of SKN-
1 signaling, extends healthy lifespan in wild type and
in a tauopathy model of C. elegans derived from aex-
3/T337 [55]. Together these data support the findings
we report here regarding ThT effects on aex-3/T337
worms’ longevity, and suggest the participation of
similar mechanisms and signaling cascades. Further
research using this and other tauopathy models will
establish the precise molecular mechanisms involved
in the reduction of tau neurotoxicity by ThT.
Treatments with ThT or the GSK-3 inhibitor
NP103 reduce the paralysis of aex-3/T337 animals,
indicating decreased neurotoxicity. This beneficial
effect could be due to the induction of autophagy-
lysosomal functions also involved the degradation of
tau aggregates [50, 51]. It is well known that ThT
mediated-protection requires this pathway [9] and
that GSK-3 inhibition triggers autophagy [56, 57].
Whether ThT could act on autophagy-lysosome sys-
tem through the inhibition of GSK-3, linking the
actions of both components to a common cellular
process dedicated to eliminate aggregated proteins
would be an interesting issue to explore in the
future.
In AD and other tauopathies GSK-3 hyperactiva-
tion is frequently accompanied by an imbalance of
tau phosphatases, such as PP2A, that contribute to
maintain tau hyperphosphorylated [58]. Therefore,
although GSK-3 inhibition would avoid the novo
phosphorylation of unphosphorylated target sites,
residues that were already phosphorylated could
remain in that state if deficiencies in phosphatases
activities occur. This could contribute to observe mild
effects of GSK-3 inhibitors, like the ones obtained
here. In addition to GSK-3, other kinases such as
Cdk5 may contribute to aex-3/T337 tau hyperphos-
phorylation that will be resistant to the use of GSK-3
inhibitors [59–61].
It is also important to take into account that
GSK-3 is part of regulatory networks where other
non-tau proteins are phosphorylated. Thus, it is dif-
ficult to determine whether the effects seen here
could be directly caused by reduced tau phospho-
rylation or by some other effect on another pathway
that indirectly influences tau-mediated uncoordinated
phenotype and lifespan shortening. In this sense, it is
well established that HSF1 and SKN-1 activities are
repressed by GSK-3 [62–65]. These two longevity
factors might be repressed in pathologies accompa-
nied by GSK-3 hyperactivity, such as tauopathies and
AD, favoring tau hyperphosphorylation and accumu-
lation. Therefore, it would be expected that GSK-3
inhibition should result in the restoration of the
activities of these two transcription factors and their
pro-longevity programs. Indeed, it has been reported
recently that the use of lithium extends Drosophila
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lifespan through inhibition of GSK-3 and activa-
tion of Nrf2-dependent hormesis [66]. However, our
data show that GSK-3 inhibition does not signif-
icantly extend lifespan in the model of tauopathy
studied here. One possible explanation would be that
lithium could modulate GSK-3 and additional signal-
ing pathways and autophagy-lysosomal degradation,
regulating longevity factors [65, 67, 68]. More selec-
tive and specific inhibitors of GSK-3, such as NP103,
would not show these lithium-combined effects.
Tetracyclines cross the blood brain barrier and
are already used in clinical practice for central ner-
vous system injury, offering the advantage of a safe
toxicological profile and well-characterized pharma-
cological properties [69–71]. Based on in vitro studies
and animal models, some drug development efforts
have been made in recent years to assess the therapeu-
tic potential of tetracyclines and derivatives in various
disorders [72]. A search of public databases (clinical-
trials.gov; drugbank.ca) shows at least three clinical
trials undertaken to assess possible clinical benefits
of tetracyclines in the treatment of AD (minocycline;
NCT01463384) or transthyretin amyloidosis (doxy-
cycline; NCT01677286).
The therapeutic effect of several GSK-3 inhibitors,
such as Lithium and Tideglusib, has been evalu-
ated in various clinical studies for the treatment
of AD and other tauopathies (see review [73]).
Some Lithium studies reported mild effects [74–76]
while Tideglusib study showed it to be safe and
a considerable improvement in cognitive function
measurements [77] and reduced the progression of
brain atrophy in patients with supranuclear progres-
sive palsy [78]. Therefore, there is an interest and
thus encourages continuing further clinical trials with
these compounds as treatment options.
It would be worth examining any synergistic
effects of ThT and NP103 on tau pathology using
combined treatments as well as to investigate whether
ThT and NP103 show therapeutic potential in studies
using other C. elegans models and mouse models of
tauopathies, including AD. If proven effective in pre-
clinical assays, next step would be to promote their
use for clinical testing in an effort to curb the pro-
gression of neurotoxic symptoms in AD and other
tauopathies.
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